Product Information
NORETHIND-ETH ESTRAD 1-0.02 MG is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.1812 per EA under NDC 68462013281. Its NADAC has been published 534 times since Jul 13, 2016.
FDA first approved this application on Jan 20, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.02; 1 mg/1; mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462013281
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETHINYL ESTRADIOL; NORETHINDRONE ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA206969FDA Approved
1/20/2016
TE Code
AB
On Market Since
1/20/2016
Price Statistics
The NADAC for NORETHIND-ETH ESTRAD 1-0.02 MG has been published 534 times since Jul 13, 2016, and over the history we have for it it has declined 76.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1812 per EA |
|---|---|
| All-time high | $0.7935 (Nov 16, 2016) |
| All-time low | $0.1619 (Nov 20, 2024) |
| 52-week high | $0.1842 |
| 52-week low | $0.1652 |
| Median price | $0.3174 |
| Average price | $0.3470 |
| Largest weekly change | +37.1% (May 22, 2019) |
| Weeks tracked | 534 |
| Tracking since | Jul 13, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Norethindrone Acetate and Ethinyl Estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone Acetate and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NORETHIND-ETH ESTRAD 1-0.02 MG?
The current National Average Drug Acquisition Cost (NADAC) for NORETHIND-ETH ESTRAD 1-0.02 MG, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.1812 per EA (NDC 68462013281), effective Sep 30, 2026.
How has the price of NORETHIND-ETH ESTRAD 1-0.02 MG changed over time?
Over the history we have for it, the NADAC for NORETHIND-ETH ESTRAD 1-0.02 MG has declined 76.4%. It has been tracked across 534 weekly CMS publications since Jul 13, 2016.
What are the highest and lowest recorded NADAC prices for NORETHIND-ETH ESTRAD 1-0.02 MG?
Since Jul 13, 2016, the NADAC for NORETHIND-ETH ESTRAD 1-0.02 MG has ranged from a low of $0.1619 (Nov 20, 2024) to a high of $0.7935 (Nov 16, 2016), with a median of $0.3174 per EA.
Are there cheaper alternatives to NORETHIND-ETH ESTRAD 1-0.02 MG?
No other NADAC-published product currently shares the active ingredient and strength of NORETHIND-ETH ESTRAD 1-0.02 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NORETHIND-ETH ESTRAD 1-0.02 MG?
NORETHIND-ETH ESTRAD 1-0.02 MG (NDC 68462013281) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.